NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Thursday reported a loss of $16.1 million in its third quarter.
The New York-based company said it had a loss of 68 cents per share.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share.
The biopharmaceutical company posted revenue of $299,400 in the period. Its adjusted revenue was $299,000.
Stemline Therapeutics shares have risen 24 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.25, a climb of 12 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML